Introduction
Merkel cell (neuroendocrine) carcinoma (MCC) is an uncommon skin malignancy with a rare incidence of distant osseous metastasis. There are only five reports of spinal metastasis from MCC in the literature [1] [2] [3] [4] [5] ; we report the sixth case.
The spine is the most common location of bony metastases, 6, 7 with an occurrence rate of up to 40% in patients with cancer.
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The thoracic spine is the most common site of disease (70%), followed by the lumbar spine (20%) and then cervical spine (10%). 8, 9 Spinal epidural lesions are the initial manifestation of malignancy in 12 to 20% of patients with cancer. 10,11 Only 10 to 20% of patients with bony metastases develop symptomatic spinal cord compression, 8, 9, 12 and 40 to 70% of those patients will have multiple levels of involvement. 13, 14 The most common primary sites accounting for the vast majority of spinal metastases are the prostate, breast, and lung, followed by renal, gastrointestinal, lymphoreticular
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Abstract
Study Design Case report.
Objective Merkel cell carcinoma (MCC), an uncommon cutaneous neuroendocrine malignancy, is a rare cause of spinal metastasis, with only five cases previously reported. We report a rare case of MCC metastatic to the spine in an immunocompromised patient.
Methods A 55-year-old male with previously resected MCC, immunocompromised due to cardiac transplant, presented with sharp mid-thoracic back pain radiating around the trunk to the midline. Computed tomography of the thoracic spine showed a dorsal epidural mass from T6 to T8 with compression of the spinal cord. Laminectomy and subtotal tumor resection were performed, and pathology confirmed Merkel cell tumor through immunohistochemistry staining positive for cytokeratin 20 and negative for thyroid transcription factor-1.
Results Further treatment with radiation therapy was initiated, and the patient did well for 4 months after surgery, but returned with a lesion in the cervical spine. He then opted for hospice care.
Conclusions With an increasing number of immunocompromised patients presenting with back pain, MCC should be considered in the differential diagnosis of spinal metastatic disease.
(lymphoma and multiple myeloma), thyroid, skin, and sarcomas, as well as unknown etiologies. The tumor appeared to extend around the cord and also into the lamina and spinous processes. Microscopic examination revealed metastatic MCC, consistent with his previous diagnosis (►Fig. 2). The diagnosis was confirmed with immunohistochemical stains positive for cytokeratin 20 (CK20) and negative for thyroid transcription factor-1 (TTF-1).
He did well postoperatively, ambulating the next day, and was discharged home. His neurologic examination became normal. Post discharge, he started radiation treatments to his back while continuing radiation treatments to his head and neck. No chemotherapy was started while awaiting his response to radiation. Use of chemotherapy with Carboplatin/ VP 16 had previously been discussed with initial nodal metastasis, but concern was raised over his immunosuppression and subsequent high risk of infection. Radiation therapy was completed 4 weeks after surgery and no chemotherapy was administered. The patient did well after surgery, reporting decreased pain and showing good strength. Nine weeks after resection of the T6 to T8 epidural mass, he presented with numbness of the soles of his feet, upper back pain and left-sided rib pain, weakness in bilateral lower extremities, and progressive gait instability. Four months after his spine surgery, the patient had developed a lesion in the cervical spine. The patient was offered surgery, but he declined. He was admitted to hospice due to progression of disease.
Discussion MCC is a rare and aggressive neuroendocrine carcinoma of the skin, with a high rate of local recurrence as well as metastasis to regional lymph nodes. Toker is credited with the first description of MCC in 1972, originally naming it trabecular carcinoma. 17 Neurosecretory granules in the tumor cells were identified by electron microscopic studies in 1978, indicating that trabecular carcinoma most likely originated from Merkel cells, one of the neural crest derivatives, 18 from which this neoplasm now gets its name. Several functions have been hypothesized for Merkel cells, including roles in chemosensation and paracrine roles in hair development, but they have generally been presumed to be mechanoreceptors.
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MCC has an incidence of 44 per 100,000. 20 It is generally a disease of the elderly, with a mean age at diagnosis of approximately 70 years, with increasing incidence with age. It is more common in whites. [20] [21] [22] The most common location of the primary tumor is the head and neck, followed by extremities, trunk, and, least commonly, an unknown primary tumor. 21, 22 At the time of diagnosis, 52% of patients have regional lymph node involvement, while 34% of patients present with distant metastasis, 21 including lungs, liver, mediastinum, para-aortic lymph nodes, and bone, in addition to local recurrence. 23, 24 Nervous system involvement is less common, though there have been eight reported cases of brain metastasis 24 in addition to the five previous cases of spinal metastasis.
1-5
Allen et al 25 found in their review of MCC patients that there was a statistically significant association between the development of distant metastasis and stage of disease at presentation. In addition, it was found that distant metastasis developed in 21% of the patients presenting with local or regional disease. Both of these findings correlate with our case and our patient's history of T2N1 Stage III MCC and regional lymph node metastases upon presentation prior to development of spinal disease. Studies have determined several presumed risk factors for MCC, including immunosuppression. [21] [22] [23] Heath et al conducted a cohort of 195 patients and found 15, or 7.8% of the patients, were immunosuppressed. Etiologies of the immunosuppression included post-organ transplantation, like the patient in this case, HIV, and chronic lymphocytic leukemia. In addition, these patients presented with more advanced disease, though there was no age difference at presentation between immunocompetent and immunocompromised patients.
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Diagnosing MCC can be difficult, as it grossly resembles several benign and malignant conditions. A definitive diagnosis of MCC is made by histologic examination as well as immunohistochemical analysis.
26,27 CK20 is both sensitive and specific for MCC; 75 to 100% of cases are focally positive for CK20. [27] [28] [29] [30] In addition, TTF-1, a marker for thyroid and pulmonary neoplasms, 31 is useful in distinguishing MCC from small cell carcinoma of the lung (SCCL). [1] [2] [3] [4] [5] The patients had varying presentations including back pain; lower extremity weakness and numbness; sciatica; lower extremity spasticity, hyperreflexia and clonus; dermatomal sensory loss and incontinence. All six patients underwent surgery. After surgery, three patients received chemotherapy, and four patients received radiation. Two patients had lumbosacral metastases, three patients had thoracic metastases, and one patient had metastases at T8, L4, and S1. Our case represents the third report of thoracic metastases.
The first case involved metastasis at T3 to T4 after the primary tumor had been treated with wide excision. Treatment included steroids and emergent radiation upon diagnosis, followed by further radiation. The patient died 23 months after diagnosis. 1 The second case involved an initial tumor treated with surgical resection and chemotherapy followed by development of right lumbosacral metastasis. This was treated with radiation and no surgical intervention was performed; the patient died more than 1 year after diagnosis. 2 The third patient had no previous history of MCC before presenting with an epidural mass with osseous involvement at the L5 to S1 levels. This patient was treated with a laminectomy and subtotal resection followed by chemotherapy, and subsequently died 2 months after diagnosis of secondary to extensive metastasis. 3 The fourth case also did not have a prior diagnosis of MCC. The patient presented with numerous neurological deficits secondary to epidural soft tissue masses causing neural compression at T8, L4, and S1. Treatment included laminectomy and tumor debulking at all three sites of compression, followed by chemotherapy and concurrent radiation. The patient died 1 month after diagnosis. 4 The fifth case involved a patient who presented with rapidly progressive paraplegia 6 months after excision of a primary Merkel cell lesion on the left brachium. The metastatic lesion at T6 required emergency decompression and stabilization. The patient died 7 months after diagnosis. 5 None of the other reported cases involved immunosuppressed patients. The previous cases were consistent with dismal long-term outcomes, reflecting the poor survival rates of advanced MCC. Allen et al conducted a review of 251 MCC patients, 14 presenting with distant metastasis. These patients had a 2-year survival rate of 11%, with a median survival of only 9 months.
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Conclusion
We present the third case of MCC metastatic to the thoracic spine, and to our knowledge, the first case of metastatic MCC in the thoracic spine in an immunocompromised patient.
With an increasing number of immunocompromised patients
Evidence-Based Spine-Care Journal Vol. 4 No. 1/2013 presenting, MCC should be considered part of the differential diagnosis of spinal metastatic disease.
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Editorial Perspective
Our practice of spine surgery is an imperfect one, despite our best attempts to always produce the best possible results. Disease recurrence and complications of treatment are hallmarks we are measured by, mostly with little regard for the patient comorbidity and disease-specific factors. As has been previously and repeatedly pointed out, rare diseases pose a particular challenge to treatment and scientific assessment as our knowledge base is often based upon anecdotal case reports, and every patient seems to present some collection of "one-out" situations. In this era of more advanced information systems and multicenter collaborative opportunities, rare cases such as this Merkel cell carcinoma should be sought and included in larger data repositories. The next step could then be taken, creating "biomaps" to allow for more granular, in-depth analysis of the genetic disease foundations, which is critical in advancing our ability to fight these rare diseases. The AOSpine Knowledge Forum movement offers a perfect home for surgeons interested in contributing to our information-gathering efforts to improve patient care.
Commentary
Aron Lazary In case of metastatic epidural tumors, the treatment is mostly palliative, but a proper staging should forego the treatment planning, especially in cases with positive medical history. In MCC, surgery is generally recommended only for single-site metastatic diseases and this tumor shows visceral spreading more often than bony involvement.
1 Neurological emergency can overwrite the above recommendation; an acute decompression surgery is to be considered in case of progressive motor weakness or bowel or bladder dysfunction. In the reported case, a simple CT of the thoracic spine seems to be not enough to carefully plan the treatment strategy even in the case where the histological diagnosis of the spinal metastasis is not surely known. MRI is highly recommended for imaging of epidural mass, but in case of its contraindication, CT-myelography can also provide more detailed data on the tumor. We agree that the debulking surgery was followed by irradiation, but according to the previously published treatment algorithms of spinal 2 and spinal epidural 3 metastases, irradiation also could have been the first treatment choice. In this reported case, 9 weeks after the subtotal resection of the thoracic epidural mass, the patient presented progressive neurological symptoms and 2 months later a cervical lesion was discovered. The judgment on indication of the index surgical treatment in the light of the progression cannot be clearly done, because in the paper, there is no information about the effectiveness of the adjuvant radiotherapy (no control CT) and about further radiological findings in these later stages.
